- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Bayer Schering alleged Lilly promoted Cialis for cardiovascular benefits and low doses based on doctor recall market research. Panel found insufficient evidence…
Anonymous HCP alleged Pfizer’s ESC 2015 exhibition stand was extravagant and created a party atmosphere, citing flavoured iced drinks. Panel found hospitality…
Complaint alleged AstraZeneca’s exhibition stand at a restaurant meeting was visible to the public. Panel found insufficient evidence and accepted precautions (private…
AstraZeneca challenged Janssen’s Invokana materials. Most dosing/compare claims were not breaches, but “flexibility” implied 300mg could be a starting dose and one…
A health professional alleged a Feraccru ad’s claim “safety profile comparable to placebo” was misleading given PI restrictions. The Panel found the…
Complaint about a BBC article calling unlicensed ocrelizumab MS trial results “landmark”. PMCPA assessed Roche’s press release (not the BBC copy) and…
Tor Generics ran a Big Issue ad with a Tor-Bac injection pack shot before MHRA licence. No breach of public POM advertising…
A health board complained about a market research recruitment email offering a ‘finder’s fee’ for AF patient interviews. PMCPA found the survey…
A Menarini disclosed 2016 transfers of value on time, but later-added R&D clinical trial payment data wasn’t uploaded to the ABPI portal…
BMS used navy/grey (not black) inverted triangles on a UK corporate products page. No breach of Clause 4.10 (not promotional), but breach…
A pharmacist alleged a Sanofi-Aventis rep misrepresented ADA/EASD guidance for Lantus and confused Acomplia study data/positioning. Panel couldn’t determine what was said…
Abbott invited renal physicians to a Zemplar advisory board with a £500 honorarium. Appeal Board said it was a genuine advisory board,…
A Pulse ‘Advertisement Feature’ for Levemir wasn’t disguised promotion, but weight-loss messaging from an uncontrolled observational study was ruled misleading, ambiguous and…
Takeda sent GPs a cost-saving leaflet referencing a PCT repeatedly but with minimal company identification. The Panel ruled it misleading/disguised promotion and…
A GP complained a Cymbalta leavepiece did not place the non-proprietary name (duloxetine) immediately adjacent to the most prominent brand name. The…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.